Injectable GLP-1s such as Wegovy have also demonstrated cardiovascular risk reduction in high-risk patients, an advantage not yet confirmed for the upcoming oral versions
This systemic reach has led researchers to explore whether lower, sustained doses of GLP-1 RAs could maintain receptor activity sufficient to preserve metabolic and organ health without the adverse events often seen with aggressive dosing
This keeps tissue healthy and absorption predictable
They may occur when patients start a GLP-1 agonist or increase their dose, and some can go away on their own over time
Lab work is included with the membership for patients who want blood work, and providers may request results before approving certain dose changes, but labs are not a gate to a prescription
Theoretically, increasing GLP-1 before a meal may decrease appetite and the amount eaten